Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
EntrestoⓇ delivers 31% growth with sales approaching
USD 1.5bn in the quarter
Sales evolution
USD m, % cc
GROWTH
Entresto
US weekly TRX1
Total prescriptions (000)
110
826
Strong Q3 momentum
■ US: robust growth outpacing market,
sales +28% cc, ~1.4m TRx in Q31
■ Ex-US: sales +34% cC
◉
China/Japan: significant contribution from HTN²
Confidence in future growth
Ex-US
US
100
+31%
90
1,485
80
70
1,135
757
60
50
565
40
30
728
570
220
10
0
Q3 2022
Q3 2023
July 2015
See last page for references.
RDP Regulatory data protection.
Sept 2023
■
Strong guidelines position³ (US/EU)
■
Expect further penetration in HF (2/3 eligible
patients still on prior SoC) and HTN (China/Japan)
■
EU: paediatric approval confirms RDP to
Nov 20264
■ US: appeal filed to uphold validity of combination
patent; other patent litigation ongoing and no
generics have FDA approval 5
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
SOC standard of care.
TRX total prescriptions. HF heart failure. HTN hypertension.
6 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation